This was a randomised, open-label phase I study with a three-way crossover design, carried out at a single centre in Görlitz, Germany. The study was performed in accordance with the Declaration ...

A total of 2306 patients were enrolled in the initial open-label phase of the study. Of these, 627 patients who showed a suboptimal response after 8 weeks of treatment with olmesartan medoxomil 20 ...

Olmesartan medoxomil, hydrochlorothiazide; 20mg/12.5mg, 40mg/12.5mg, 40mg/25mg; tabs. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of ...